Amgen management check
AMGN · Health Care · Biotechnology · CEO Mr. Bradway
Filings as of
Closest peers in Biotechnology
- 38GILDGilead Sciences83
- 50VRTXVertex Pharmaceuticals81
- 88REGNRegeneron Pharmaceuticals77
- 111AMGNAmgen76
- 208ABBVAbbVie68
- 300INCYIncyte61
- 405MRNAModerna53
- 439BIIBBiogen48
The seven checks
- WatchTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
3339thDetail
$100 invested at the start of fiscal 2021 grew to $167, against $192 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
8352ndDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.67 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good0.3% of net income
What does the CEO cost owners?
$24.7m pay · $7.7bn net income, FY2025
9188thDetail
$24.7m of reported pay in fiscal 2025, against $7.7bn of net income.
- WatchInsiders are selling
Do they own the stock?
6 mo: ▲ $0 bought · ▼ $4.1m sold
——Detail
3 insiders sold $4.1m in the last six months and none bought.
- WatchShare count growing
Are owners being diluted?
Diluted shares +0.4% a year; flagged above +2%
Stock pay 1.3% of revenue
4526thDetail
Diluted shares changed +0.4% a year over the last three fiscal years. Stock-based pay was 1.3% of revenue in the latest year.
- Good5 leadership filings in 3 years
Is leadership stable?
5 filings under 8-K 5.02 in 3 years
CEO: Mr. Bradway
100100thDetail
CEO in the pay table: Mr. Bradway. 5 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 7, 2026.
Pay tied most to non-GAAP, earnings per share, or EPS
Other key measuresNon-GAAP earnings per share (EPS)Non-GAAP return on invested capital (ROIC)Total shareholder return (TSR) relative to that of the S&P 500RevenuesNon-GAAP net incomePipeline, clinical study, and regulatory goalsWorkforce and technology goals
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Mr. Bradway | $24.7m | $49.4m | $8.5m | $167 | $192 | $7.7bn |
| 2024 | — | $24.4m | $12.7m | $9.8m | $129 | $150 | $4.1bn |
| 2023 | — | $22.6m | $29.1m | $7.7m | $138 | $138 | $6.7bn |
| 2022 | — | $21.4m | $41.7m | $7.2m | $121 | $136 | $6.6bn |
| 2021 | — | $21.7m | $17.0m | $7.4m | $101 | $123 | $5.9bn |
Insiders and the CEO's stakeSelling
3 insiders sold $4.1m in the last six months and none bought.
Open-market trades by officers and directors since May 21, 2026.
- SoldDerek MillerSVP, Human Resources$1.6mAug 6, 2026
- SoldRachna KhoslaSVP, Business Development$1.3mAug 13, 2026
- SoldNancy A. GrygielSVP & CCO$1.2mAug 6, 2026
Leadership and governance on file
All 7 filings
- Oct 27, 2026Leadership change8-K 5.02
- May 19, 2026Leadership change8-K 5.02
- Apr 22, 2026Leadership change8-K 5.02
- Jun 3, 2024Leadership change8-K 5.02
- Dec 14, 2023Leadership change8-K 5.02
- Aug 4, 2023Leadership change8-K 5.02
- Aug 3, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 20, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $34.3bn returned to owners in buybacks and dividends, 111% of net income, and $2.2bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $26.0bn | $26.3bn | $28.2bn | $33.4bn | $36.8bn |
| Net income | $5.9bn | $6.6bn | $6.7bn | $4.1bn | $7.7bn |
| Stock-based pay | $341.0m | $401.0m | $431.0m | $530.0m | $494.0m |
| Buybacks | $5.0bn | $6.4bn | $0 | $200.0m | $0 |
| Dividends | $4.0bn | $4.2bn | $4.6bn | $4.8bn | $5.1bn |
| Diluted shares | 573m | 541m | 538m | 541m | 542m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.